Arrowhead Common Stock vs Other Current Assets Analysis
ARWR Stock | USD 26.03 0.12 0.46% |
Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Common Stock and its Other Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.
Common Stock vs Other Current Assets
Common Stock vs Other Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Common Stock account and Other Current Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between Arrowhead Pharmaceuticals' Common Stock and Other Current Assets is 0.71. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Arrowhead Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Common Stock and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Arrowhead Pharmaceuticals are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Common Stock i.e., Arrowhead Pharmaceuticals' Common Stock and Other Current Assets go up and down completely randomly.
Correlation Coefficient | 0.71 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Common Stock
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Issuance Of Capital Stock is relatively stable compared to the past year. As of 12/01/2024, Enterprise Value is likely to grow to about 3.3 B, while Selling General Administrative is likely to drop slightly above 93.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 243.2M | 240.7M | 3.6M | 3.4M | Total Revenue | 243.2M | 240.7M | 3.6M | 3.4M |
Arrowhead Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Arrowhead Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arrowhead Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 522.5M | 710.1M | 691.9M | 765.6M | 1.1B | 1.2B | |
Other Current Liab | 32.8M | 33.3M | 100.4M | 58.2M | 85.4M | 89.7M | |
Total Current Liabilities | 40.7M | 146.5M | 74.1M | 105.5M | 103.2M | 108.3M | |
Total Stockholder Equity | 461.8M | 408.8M | 106.0M | 271.3M | 185.4M | 93.8M | |
Property Plant And Equipment Net | 47.0M | 66.0M | 168.6M | 335.6M | 431.3M | 452.9M | |
Net Debt | (122.4M) | (158.9M) | (26.4M) | 4.3M | 14.7M | 15.4M | |
Retained Earnings | (503.8M) | (644.7M) | (820.8M) | (1.0B) | (1.6B) | (1.5B) | |
Accounts Payable | 6.8M | 9.5M | 2.9M | 35.9M | 11.4M | 12.0M | |
Cash | 143.6M | 184.4M | 108.0M | 110.9M | 102.7M | 53.4M | |
Non Current Assets Total | 200.1M | 325.6M | 315.5M | 346.0M | 444.3M | 466.5M | |
Non Currrent Assets Other | 265.4K | 272K | 29.1M | 210K | 4.5M | 4.7M | |
Cash And Short Term Investments | 315.5M | 367.8M | 376.4M | 403.6M | 681.0M | 715.0M | |
Net Receivables | 327.4K | 661.4K | 845.7K | 10.3M | 1.4M | 0.0 | |
Common Stock Total Equity | 187.9K | 194.7K | 197K | 198K | 227.7K | 239.1K | |
Common Stock Shares Outstanding | 100.7M | 103.7M | 105.4M | 106.8M | 119.8M | 125.8M | |
Liabilities And Stockholders Equity | 522.5M | 710.1M | 691.9M | 765.6M | 1.1B | 1.2B | |
Inventory | 3.3M | 4.3M | 4.4M | (21.6M) | (19.5M) | (18.5M) | |
Other Current Assets | 6.0M | 6.6M | 27.5M | 15.9M | 14.5M | 15.2M | |
Other Stockholder Equity | 965.4M | 1.1B | 1.2B | 1.3B | 1.8B | 1.9B | |
Total Liab | 60.7M | 301.3M | 586.0M | 478.4M | 948.7M | 996.2M | |
Property Plant And Equipment Gross | 47.0M | 88.9M | 110.3M | 377.5M | 489.3M | 513.8M | |
Total Current Assets | 322.4M | 384.6M | 376.4M | 419.5M | 695.5M | 730.2M | |
Accumulated Other Comprehensive Income | 18.4K | (69K) | (136K) | (3.2M) | 4.8M | 5.0M | |
Short Term Debt | 1.1M | 4.5M | 5.6M | 9.7M | 6.3M | 6.7M | |
Common Stock | 194.7K | 197K | 106.0M | 200K | 217K | 206.2K | |
Current Deferred Revenue | 19.3M | 111.1M | 74.1M | 866K | 995.9K | 946.1K | |
Non Current Liabilities Total | 20.0M | 154.8M | 511.9M | 372.9M | 742.4M | 779.5M | |
Property Plant Equipment | 30.9M | 48.7M | 110.3M | 335.6M | 385.9M | 405.2M | |
Other Assets | 68.9M | 96.8M | 218K | 210K | 241.5K | 229.4K | |
Short Term Investments | 171.9M | 183.4M | 268.4M | 292.7M | 578.3M | 607.2M | |
Intangible Assets | 15.4M | 13.7M | 12.0M | 10.3M | 8.6M | 10.2M | |
Other Liab | 8.7M | 41.4M | 190.3M | 56.0M | 64.3M | 67.6M | |
Net Tangible Assets | 446.4M | 395.2M | 398.5M | 261.1M | 300.2M | 202.9M |
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Arrowhead Stock
0.37 | BHC | Bausch Health Companies | PairCorr |
0.35 | HCM | HUTCHMED DRC | PairCorr |
0.32 | GANX | Gain Therapeutics | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.